[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,776,632
  • Shares Outstanding, K 42,447
  • Annual Sales, $ 3,183 M
  • Annual Income, $ 1,335 M
  • EBIT $ 1,436 M
  • EBITDA $ 1,521 M
  • 60-Month Beta 0.57
  • Price/Sales 7.35
  • Price/Cash Flow 16.27
  • Price/Book 3.86

Options Overview Details

View History
  • Implied Volatility 30.74% (-0.60%)
  • Historical Volatility 22.08%
  • IV Percentile 4%
  • IV Rank 2.42%
  • IV High 92.62% on 08/25/25
  • IV Low 29.21% on 12/05/25
  • Expected Move (DTE 27) 13.98 (2.61%)
  • Put/Call Vol Ratio 3.35
  • Today's Volume 1,026
  • Volume Avg (30-Day) 1,220
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 28,687
  • Open Int (30-Day) 26,128
  • Expected Range 522.61 to 550.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $6.84
  • Number of Estimates 5
  • High Estimate $7.48
  • Low Estimate $6.07
  • Prior Year $6.41
  • Growth Rate Est. (year over year) +6.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
532.59 +0.75%
on 06/18/26
580.39 -7.55%
on 05/27/26
-30.40 (-5.36%)
since 05/18/26
3-Month
517.59 +3.67%
on 03/24/26
609.35 -11.94%
on 05/06/26
+6.24 (+1.18%)
since 03/18/26
52-Week
272.12 +97.19%
on 07/31/25
609.35 -11.94%
on 05/06/26
+244.87 (+83.94%)
since 06/18/25

Most Recent Stories

More News
These 3 Stocks Lowered Their Share Counts Drastically in Q1

Pinterest, Southwest Airlines, and United Therapeutics each executed significant share repurchases in Q1 2026, reducing their outstanding share counts by 16%, 5%, and 3.2%, respectively.

PINS : 20.27 (-0.44%)
LUV : 47.97 (+2.81%)
UTHR : 536.59 (-2.70%)
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore

1 Cash-Producing Stock with Exciting Potential and 2 We Ignore

VSTS : 12.88 (+0.63%)
CNX : 32.67 (-0.52%)
UTHR : 536.59 (-2.70%)
2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down

2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down

NVMI : 575.31 (+3.77%)
SYF : 75.26 (+1.55%)
UTHR : 536.59 (-2.70%)
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on...

UTHR : 536.59 (-2.70%)
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis ( IPF ) preserved lung function...

UTHR : 536.59 (-2.70%)
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening...

UTHR : 536.59 (-2.70%)
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

First-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDA

UTHR : 536.59 (-2.70%)
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

UTHR : 536.59 (-2.70%)
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on...

UTHR : 536.59 (-2.70%)
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis ( IPF ) include efficacy and safety results from ...

UTHR : 536.59 (-2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 572.99
2nd Resistance Point 564.11
1st Resistance Point 550.35
Last Price 536.59
1st Support Level 527.71
2nd Support Level 518.83
3rd Support Level 505.07

See More

52-Week High 609.35
Last Price 536.59
Fibonacci 61.8% 480.53
Fibonacci 50% 440.73
Fibonacci 38.2% 400.94
52-Week Low 272.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.